Biophytis Receives Approval from the French Health Authority (ANSM) to Initiate COVA, a Clinical Trial with Sarconeos (BIO101) for the Treatment of COVID-19 Related Respiratory Failure

27 Jul 2020 08:00 CEST

Company Name

BIOPHYTIS

ISN

FR0012816825

Market

Euronext Growth

Symbol

ALBPS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_937859_Biophytis__COVA_ANSM_Approval__EN_PR_FINAL.pdf

Source

BIOPHYTIS

Provider

Les Echos

Attachments

  • Original document
  • Permalink

Disclaimer

Biophytis SA published this content on 27 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 July 2020 07:15:16 UTC